GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (XAMS:BAI) » Definitions » Net Cash per Share

Benevolent AI (XAMS:BAI) Net Cash per Share : €0.06 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Benevolent AI's Net Cash per Share for the quarter that ended in Dec. 2023 was €0.06.

The historical rank and industry rank for Benevolent AI's Net Cash per Share or its related term are showing as below:

XAMS:BAI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.48   Med: 12.24   Max: 18
Current: 8.8

During the past 6 years, the highest Price-to-Net-Cash Ratio of Benevolent AI was 18.00. The lowest was 6.48. And the median was 12.24.

XAMS:BAI's Price-to-Net-Cash is ranked worse than
72.78% of 867 companies
in the Biotechnology industry
Industry Median: 4.04 vs XAMS:BAI: 8.80

Benevolent AI Net Cash per Share Historical Data

The historical data trend for Benevolent AI's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Net Cash per Share Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial 0.49 0.46 0.09 0.54 0.06

Benevolent AI Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only 0.09 1.01 0.54 0.35 0.06

Competitive Comparison of Benevolent AI's Net Cash per Share

For the Biotechnology subindustry, Benevolent AI's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benevolent AI's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Price-to-Net-Cash falls into.



Benevolent AI Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Benevolent AI's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(42.341-34.312-0)/124.44
=0.06

Benevolent AI's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(42.341-34.312-0)/124.44
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benevolent AI  (XAMS:BAI) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Benevolent AI Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Benevolent AI (XAMS:BAI) Business Description

Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.

Benevolent AI (XAMS:BAI) Headlines

No Headlines